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Abstract Imatinib mesylate (IM) is a frontline treatment
in the early chronic phase of chronic myeloid leukemia
(CML). However, intrinsic and acquired resistance against
this drug has been defined and this issue has become a
problem and a challenge in CML treatment. According to
new findings, the inhibition of Janus kinase 2 (Jak2) in
Bcr–Abl+ cells can promote apoptosis in IM-resistant
cells. microRNAs (miRNAs) regulate the gene expression
by targeting the messenger RNA (mRNA) for degrada-
tion. Recently, a growing body of evidence has implicated
that dysregulation of miRNAs is associated with cancer
initiation and development. In this report, we proposed
that miRNA-101 targets Jak2 mRNA and regulates its
expression and induces K562 leukemia cell apoptosis.
Here, we transduced the K562 cell line with a miR-101-
overexpressing vector and evaluated the Jak2 mRNA lev-
el. Our results showed that miR-101 overexpression in
Bcr–Abl+ cel ls reduced the Jak2 mRNA level .
Moreover, imatinib treatment and miR-101 upregulation
led to miR-23a overexpression, which has putative bind-
ing site(s) on 3′-untranslated regions (3′-UTRs) of STAT5,
CCND1, and Bcl-2 genes. Our results also indicated that
miR-101 overexpression inhibited cell proliferation
indicated by the MTT assay and promoted apoptosis de-
tected via flow cytometry. Importantly, mRNA expression
of NF-kappa B-regulated anti-apoptotic (Bcl-2, Bcl-xl,
MCL-1, XIAP, and survivin) and proliferative (c-Myc
and CCND1) genes was decreased. These findings sug-
gest that miR-101 acts as a tumor suppressor by downreg-
ulating Jak2 expression and sensitizing K562 cells to i-
matinib. Therefore, restoration of miR-101 may be a ther-
apeutic approach for CML treatment.
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Introduction
Chronic myeloid leukemia (CML) is a clonal myeloprolifera-
tive disorder associated with the presence of the Philadelphia
chromosome (Ph) that results from a reciprocal translocation
between chromosome 9 and 22, t(9;22), that encodes the Bcr–
Abl fusion protein [1]. Bcr–Abl activates different signaling
pathways including the Ras/Raf/MAPK, PI3K/AKT/mTOR,
and JAK/STAT pathways [2–4]; hence, it causes chronic mye-
loid leukemia cell proliferation, abnormal interactions with the
extracellular matrix and stroma [5], and impaired apoptosis [6].
Discovery of tyrosine kinase inhibitors (TKIs) has rev-
olutionized the treatment of CML [7]. The most well
known TKI, imatinib, inhibits the Bcr–Abl activity and
blocks its downstream signaling pathways. However, a
major obstacle to its success is the development of thera-
peutic resistance as a result of mutations in the Bcr–Abl
tyrosine kinase domain (for example, T315I) [8], increas-
ing the copy number of the Bcr–Abl gene [9], and a Bcr–
Abl independent mechanism involving Lyn kinase (for
example, K562-R cells) [10].
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Jak2 tyrosine kinase activated by the Bcr–Abl oncoprotein
has a critical role in Bcr–Abl-mediated oncogenicity [11, 12].
There is some evidence that shows that the Bcr–Abl/Jak2
complex stabilizes the Bcr–Abl kinase activity [13].
Therefore, Jak2 inhibition can overcome the resistance to i-
matinib treatment through the induction of apoptosis in
imatinib-resistant cell lines and primary samples of blast crisis
(BC) CML patients [14].
MicroRNAs (miRNAs) are a group of endogenously
expressed, ~22-nucleotide-long, non-coding small RNAs
that are known to negatively regulate the expression of up
to 30 % of the human genes by directly binding to the 3′-
untranslated region (UTR) of target messenger RNAs
(mRNAs) [15]. miRNAs follow two mechanisms for gene
silencing: translation repression and/or degradation of the
target mRNAs [16]. miRNAs have been found to play
important roles in several biological processes including
cellular development, apoptosis, differentiation, and tu-
mor growth [17]. Increasing evidence from experimental
studies indicates that miRNAs might be involved in can-
cer by functioning as oncogenes or tumor suppressors
[18]. Based on increasing studies, miRNAs may play a
role in the chemosensitivity and chemoresistance of hu-
man cancer cells [19, 20]; for example, upregulation of
miR-424 sensitized K562 cells to imatinib [21]. miR-29b
has been shown to augment apoptosis induction by
bortezomib in multiple myelomas [22]. miR-101 is a
member of a family of miRNAs that are involved in a
wide range of cellular activities, like cell proliferation,
invasion, and angiogenesis [23]. miR-101-coding genes
are located in the genomic fragile regions so that they
are prone to being deleted or amplified in several cancers
[24]. In particular, several studies have demonstrated that
miR-101 can suppress the oncogenic signal transduction
in breast [25], ovarian [23], and gastric cancers [26];
hence, miR-101 can play a tumor-suppressive role in tu-
mor cell growth, migration, invasion, and drug resistance.
Several studies have indicated that miR-101 downregula-
tion correlates inversely with increased EZH2 and MCL-1
expression levels in many cancer cell types [27]. Lu Wang
et al. demonstrated that miR-101 suppressed the tumor
cell growth and promoted apoptosis in breast cancer cells
by targeting Jak2 [28]. So, it seems that Jak2 inhibition by
miR-101 with regard to Jak2’s crucial role in Bcr–Abl-
mediated oncogenicity promotes apoptosis and suppresses
Jak2-regulated pathways. In the current study, we investi-
gated the therapeutic potential of miR-101 in K562 cells
as a chemosensitizer for imatinib treatment. Our results
reveal the anti-tumor effects of miR-101 in K562 leuke-
mia cells by targeting Jak2 and NF-κB anti-apoptotic tar-
get genes. These findings strongly suggest that upregula-
tion of miR-101 in CML cells has a role in enhancing
drug sensitivity to imatinib.
Materials and methods
Cell culture
K562 cells were grown in the RPMI-1640 medium supple-
mented with 2 mM L-glutamine, 10 % fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin
in an incubator with 5 % CO2 and 95 % humidity at 37 °C
(Memert, Germany). The HEK 293Tcells (kindly provided by
Dr. Frank Grosveld, Erasmus MC) used for the production of
lentiviruses were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % FBS and penicil-
lin–streptomycin.
Cell death analysis by flow cytometry
Cell viability was determined by the propidium iodide (PI)-
exclusion test. Because the intact membrane of the live cells
excludes charged dyes like PI, short-term incubation of these
dyes results in selective labeling of the dead cells, whereas live
cells have no or minimal uptake. Cells were incubated with
10 μg/ml PI for 10 min prior to flow cytometric analysis using
a FACSCalibur flow cytometer (BD Biosciences, San Jose,
CA, USA). Data was analyzed using the CellQuest software
(BD Biosciences).
Metabolic activity measured by the MTT assay
The effect of Jak2 downregulation on the proliferation of
K562 cells was assessed by the MTT colorimetric method.
Briefly, miR-101-transduced cells and negative control
(NC)-transduced cells were seeded into a 96-well culture plate
at a density of 10 × 103 cells/well. Some of the wells were
treated with 250 nM of imatinib and incubated for 72 h. After
removing the medium, the cells were incubated with MTT
solution (5 mg/ml in PBS) for 4 h and the resulting formazan
was solubilized with DMSO (100 μl). The absorbance of each
well was measured at 570 nm in an ELISA reader.
Sub-G1 DNA content analysis
Apoptotic cells were detected using PI staining of
miRNA-transduced cells followed by flow cytometry to
detect the so-called sub-G1 peak. Briefly, 7 days after
removal of the virus-containing medium, 0.4 × 106 cells
were detected by flow cytometry. Transduced cells were
then harvested and washed once in PBS and fixed with
70 % ethanol. Then, the cells were treated with 0.5 μg/ml
RNase in PBS and incubated at 37 °C for 30 min be-
fore staining with 50 μg/ml PI for 30 min. The cells
were analyzed using a FACScan flow cytometer (Becton
Dickinson).
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Phosphatidylserine externalization (Annexin V assay)
The Annexin V binding assay was performed to detect apo-
ptosis in Jak2 downregulated cells. The K562 transduced cells
were treated with 250 nM of imatinib for 72 h and were then
washed with PBS after the incubation time. A total of
0.4 × 106 cells were washed with PBS and resuspended in a
total volume of 100 μl of the incubation buffer. Annexin V
(5 μl per sample) (BD Biosciences, USA) was added, and the
cell suspension was incubated for 20 min in the dark.
Fluorescence was then measured using flow cytometry. The
data was evaluated using the CellQuest software (Becton
Dickinson) and expressed as percentage of the cells positive
for Annexin V (early apoptotic phase).
Lentiviral production and infection
On the first day, 5 × 106 HEK-293Tcells were seeded in a 10-
cm dish. In the next morning, the HEK293T cells were
transfected with GFP hsa-miR-101-1 Lentivector and
pLenti-III-mir-GFP-Blank (ABM Inc., Canada) together with
two packaging vectors (psPAX2 and pMD2.G) using X-
tremeGENE™ HP DNA Transfection Reagent (Roche
Diagnostics). Lentivirus-containing supernatants were har-
vested at 48 and 72 h after transfection and filtered through
a low-protein binding 0.45-μM sterile filter (Merck Millipore
Ltd). To infect the cells, a virus-containing medium supple-
mented with 8 μg/ml SureENTRY™ Transduction Reagent
(Qiagen) was added to 2 × 105 K562 cells in 24-well plates.
The viral supernatant was replaced with normal culture medi-
um after 24 h, and infection efficiency was monitored by GFP
expression at 48 h after infection.
RNA preparation and quantitative real-time PCR
For reverse transcription PCR (RT-PCR), the total RNA
with miRNA was purified using the miRNeasy Mini Kit
(Qiagen) following the manufacturer’s instruction. One
microgram of the isolated RNA was used for the prepara-
tion of cDNA using the miScript II RT Kit (Qiagen). The
level of miRNAs was quantified using the miScript SYBR
Green PCR Kit and miScript Primer Assay (Qiagen) in
the StepOnePlus Real-Time PCR System (Applied
Biosystems, Foster City, USA). The data was normalized
to U6 expression (Qiagen). The qRT-PCR of mRNA tem-
plates (1 μg) was performed using the RealQ Plus 2×
Master Mix Green High ROX™ (Ampliqon, PCR en-
zymes & Bioreagents, Denmark) in the StepOnePlus
Real-Time PCR System (Applied Biosystems, Foster
City, USA). Values are expressed as relative expression
of mRNA normalized to the housekeeping GAPDH
mRNA. Relative quantification (RQ) values were calcu-
lated as 2−ΔΔCt by the comparative Ct method. The
experiment was repeated three times and representative
data sets are shown. Primer sequences for determining
mRNA level are available upon request.
Statistical analysis
All data were analyzed using the IBM SPSS software (version
20). All numerical data were generated from three indepen-
dent experiments and are presented as means ± SEM.
Differences between groups were examined using the
Student’s t test. A two-tailed difference with P < 0.05 was
considered statistically significant.
Results
miR-101 has inhibitory effect on K562 cell viability index
In order to investigate the effect of miR-101 on the induction
of cell death, two groups of cells including miR-101-
transduced and NC-transduced cells were analyzed using PI
staining followed by flow cytometry. As shown in Fig. 1a,
miR-101 overexpression induced cell death as indicated by
the increased percentage of dead cells. To evaluate cell prolif-
eration, the MTT assay was performed on miR-101-
transduced and negative control cells 7 days after the removal
of the lentivirus-containing medium. As shown in Fig. 1b, the
population of miR-101-overexpressed cells was significantly
decreased compared to the NC-transduced cells.
miR-101 induces a cytotoxic effect through apoptosis
in K562 cells
To address whether miR-101-induced cell death in K562 cells
was due to apoptosis, we evaluated the modulation of
phosphatidylserine externalization as an indicator of early ap-
optosis in K562 leukemia cells by flow cytometry. Our results
showed that the percentage of Annexin V-positive transduced
cells was significantly increased compared to NC-transduced
cells (Fig. 2). Altogether, these findings suggest that miR-101
overexpression induces apoptosis in chronic myeloid leuke-
mia CML K562 cells.
miR-101 influences cell cycle progression of K562
leukemia cells
As miR-101 overexpression influences K562 leukemia
cell proliferation, we evaluated cell cycle changes in leu-
kemia cells after miR-101 upregulation. The results of
flow cytometry showed that miR-101 overexpression
caused an arrest in the G0/G1 phase and blocked cells
before the S phase (Fig. 3). As shown in Fig. 3, overex-
pression of miR-101 led to G0/G1 arrest and the
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proportion of sub-G1 apoptotic cells was also significant-
ly increased. These findings suggest that miR-101 arrests
K562 leukemia cells at the G0/G1 phase, thereby
inhibiting cell cycle progression.
Transduction of miR-101 augments the effect of imatinib
in inducing apoptosis of K562 cells
Imatinib treatment reduced cell viability and increased the
apoptotic rate of K562 cells compared to untreated cells.
miR-101 overexpression enhances the apoptosis-inducing ef-
fect of imatinib on K562 cells. To assess the effect of miR-101
and imatinib on apoptosis in K562 cells, we evaluated the
modulation of phosphatidylserine externalization after trans-
duction and imatinib treatment. We found that imatinib treat-
ment of miR-101-transduced cells increased apoptosis rather
than either alone (Figs. 2 and 4a). Moreover, cell viability and
cell proliferation were more affected after treatment of miR-
101-trancduced cells by imatinib compared to untreated miR-
101-transduced cells and NC-transduced cells with or without
imatinib treatment (Figs. 1a, b and 4b, c). Collectively, these
results indicate that transduction of miR-101 enhances the
imatinib-induced cytotoxicity.
Jak2 and MCL-1 may be targets for miR-101
In order to identify the potential targets of miR-101, we
performed gene expression analysis using the miR-101-
transduced K562 cells relative to NC-transduced cells.
First, we identified 11 genes to be downregulated by the
miR-101 overexpression. Then, using two online predic-
tion software programs (TargetScan.org and miRNA.org)
that have high precision and sensitivity [29, 30], we found
that only two of them could be predicted targets for miR-
101. To show that miR-101 negatively regulated these two
genes, we transduced K562 cells by the miR-101 expres-
sion vector (Fig. 5a, b) Interestingly, we noticed that Jak2
and MCL-1 that contained putative binding site(s) on their
3′-UTRs (Fig. 5c) were considerably downregulated in
miR-101-transduced K562 cells (Fig. 5d). In agreement
with this finding, a negative correlation was seen between
endogenous miR-101 level and Jak2 and MCL-1 mRNA
expression in K562 cells transduced by miR-101. Our
Annexin-V (PE)
Fig. 2 Apoptotic effect of miR-101 overexpression on K562 cells. K562
cells were transduced with miR-101 and NC vectors. Cells were analyzed
for Annexin V by flow cytometry. Results showed increased apoptosis in
K562 cells overexpressing miR-101 compared with those in the vector
control cells. One representative experiment of at least three performed is
presented
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Fig. 1 Effects of miR-101 overexpression on cell proliferation and cell
death in K562 cells. amiR-101 induces cell death in K562. Cell viability
was detected by PI assay in K562-transduced and NC-transduced groups
and analyzed by flow cytometery. One representative experiment of at
least three performed is presented. b Cell proliferation assay of K562-
tansduced cells. Transduced cells were grown in complete medium, and
cell growth was measured by MTTassay. The metabolic activity of miR-
101-transduced cells was decreased. The results are expressed as
mean ± SD of at least three independent experiments (*P < 0.05
relative to NC-transduced cells). Con = control
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Fig. 4 Effects of imatinib on apoptosis and cell proliferation in K562-
transduced cells. a Transduced cells were treated with 250 nM imatinib
for 72 h. Cells were analyzed for Annexin V by flow cytometry. Results
showed that miR-101 overexpression enhances imatinib-induced
apoptosis. One representative experiment of three performed is shown.
b Imatinib induces cell death in miR-101 and NC-transduced cells.
Transduced cells were treated with 250 nM of imatinib and cultured for
72 h. Then, cell death was analyzed for PI by flow cytometery. One
representative experiment of at least three performed is presented. c
Cell proliferation assay of imatinib treated K562-transduced cells. Cells
were cultured in complete medium with 250 nM of imatinib in 96-well
plates for 72 h, and cell growth was measured by MTTassay. The results
are expressed as mean ± SD of at least three independent experiments
(*P < 0.05 relative to NC-transduced cells)
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Fig. 3 Effects of miR-101 on cell cycle distribution in K562 cells. K562
cells were transduced with miR-Con or miR-101. Cells were collected,
stained with PI, and processed for analysis by flow cytometry to measure
DNA content. Flow cytometry data was analyzed to determine cell cycle
distribution (G0/G1, S, and G2/M) in the surviving cell populations. One
representative experiment of at least three performed is presented
(*P < 0.05 relative to NC-transduced cells)
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data also showed that imatinib treatment of miR-101-
transduced K562 cells and NC-transduced cells resulted
in increased Jak2 and MCL-1 mRNA levels as compared
to untreated cells, which was associated with the effect of
imatinib on miR-101 downregulation (Fig. 5e, f). These
observations indicate that imatinib treatment leads to miR-
101 downregulation that negatively regulates Jak2 and
MCL-1 expression.
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Transduction of CML cell line (K562) with miR-101
reduced c-Myc and hTERT expression
It has been shown that the transcription factor c-Myc is required
for Bcr–Abl transformation [31]. Furthermore, Xie et al.
showed that Jak2 was involved in c-Myc overexpression
[12]. A growing body of data indicates that various transcrip-
tion factors regulate the human telomerase reverse transcriptase
(hTERT) expression by acting on the hTERT promoter, and it
seems that c-Myc is a strong regulator of the hTERT gene
expression [32, 33]. Due to Jak2 downregulation in miR-101-
transduced cells and given the regulatory role of Jak2 in c-Myc
and hTERT mRNA expression, we evaluated c-Myc and
hTERT mRNA levels 7 days after removal of the lentivirus-
containing medium using the qRT-PCR. As presented in
Fig. 6a, c-Myc and hTERT mRNA levels decreased in miR-
101-transduced cells compared to NC-transduced cells.
Imatinib treatment reduced the hTERTmRNA level rather than
miR-101 overexpression (Fig. 6a, c). We also showed that ima-
tinib treatment enhanced the effect of miR-101 overexpression
in c-Myc and hTERT mRNA downregulation (Fig. 6b, c).
miR-101 overexpression downregulates STAT5, Bcl-2,
and CCND1 mRNA levels via upregulation of miR-23a
As shown in Fig. 7a, miR-101 overexpression and imatinib
treatment led to upregulation of the miR-23a expression. A
bioinformatic analysis (http://www.targetscan.org/) found
putative target sites of miR-23a in the 3ʹ-UTR of signal trans-
ducer and activator of transcription (STAT) 5, cell cycle regu-
lator gene CCND1, and anti-apoptotic gene Bcl-2 (Fig. 7b).
STAT5 is constitutively active in Bcr–Abl+ cells [34] that sup-
port a leukemogenic role for this transcription factor in CML. It
has been reported that CCND1 is a key regulator of the G1/S
transition [35] and Bcl-2 is known as an anti-apoptotic gene
[36]. Our results showed that STAT5, CCND1, and Bcl-2
mRNA levels decreased in miR-101-transduced cells
(Fig. 7c). We also showed that imatinib enhanced the miR-
101 overexpression effect on upregulation of miR-23a and
downregulation of these three mRNAs. These observations in-
dicate that STAT5, CCND1, and Bcl-2 genes may serve as
targets for miR-23a, which was overexpressed upon miR-101
upregulation or imatinib treatment in K562 cells.
miR-101-induced downregulation of the STAT5
expression in the K562 cell line promotes apoptosis
It has been reported that increased STAT5 expression results
in resistance to TKI treatment [37]; the molecule is now
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Fig. 6 miR-101 expression
executes transcriptional
suppression of c-Myc and
hTERT. a Real-time PCR showed
c-Myc and hTERT (normalized to
GAPDH) downregulation in
K562 cells after miR-101
overexpression. b, c Down
modulation of c-Myc and hTERT
following imatinib treatment.
miR-101 and NC-transduced cells
were treated with 250 nM
imatinib for 72 h, after which
RNAwas harvested, and
expression of the indicated genes
was measured using quantitative
RT-PCR and normalized to the
expression of GAPDH. The
figure shown is a representative of
at least three independent
experiments (*P < 0.05 relative to
NC-transduced cells)
Fig. 5 Upregulated miR-101 significantly affected Jak2 and MCL-1
expression. a Verification of miR-101 transduction. The qRT-PCR
showed that expression level of miR-101 is nine times than the normal
time. The difference was statistically significant. b The fluorescence
microscopy image showed miR-101 expression in K562 cells. c Two
predicted miR-101 target sites in the 3′-UTR of Jak2 and one predicted
miR-101 target site in the 3′-UTR of MCL-1. The seed sequences of the
two miRNAs are bolded, and the matched or complementary nucleotides
between the miRNAs and the Jak2 and MCL-1 3′-UTR are indicated. d
Jak2 and MCL-1 downregulation (normalized to GAPDH) in microRNA-
transduced cells analyzed by real-time PCR. e, f Imatinib treatment of miR-
101 and NC-transduced K562 cells leads to Jak2 and MCL-1 upregulation
in qRT-PCR compared to untreated cells, which is associated withmiR-101
expression. One representative experiment of at least three performed is
presented (*P < 0.05 relative to NC-transduced cells)
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considered a potential therapeutic target in CMLCD34+ cells.
We observed a significantly decreased expression of STAT5
accompanied by decreased STAT5 target genes Bcl-xL,MCL-
1, and Bcl-2 (Figs. 8, 5d, and 7c). Furthermore, STAT5 was
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downregulated upon imatinib treatment in both miR-101-
transduced and NC-transduced cells. Interestingly, the miR-
101 overexpression augmented the imatinib effect on STAT5
downregulation. The data confirmed that miR-101 overex-
pression in combination with imatinib treatment resulted in
the downregulation of STAT5 and its anti-apoptotic target
genes Bcl-xL, MCL-1, and Bcl-2, inducing apoptosis
(Figs. 8, 5e, f, and 7c).
miR-101 induced downregulation of NF-κB-regulated
anti-apoptotic genes
Chronic myeloid leukemia is characterized by the Bcr–Abl
fusion protein that can activate the NF-κB pathway [38].
Interestingly, it has been reported that Jak2 is involved in
NF-κB activation by Bcr–Abl [39]. It is of interest to note that
NF-κB can promote the cellular growth process through the
regulation of specific target genes like CCND1 and c-Myc
[40]. Furthermore, NF-κB directly regulates a range of anti-
apoptotic genes including Bcl-2, Bcl-xL, MCL-1, XIAP, and
survivin [41]. In our study, qRT-PCR showed that CCND1, c-
Myc, Bcl-2, MCL-1, Bcl-xL, XIAP, and survivin mRNA
levels were significantly downregulated in miR-101-
transduced cells compared to NC-transduced cells (Figs. 7c,
6a, 5d, 8, and 9). These findings revealed that miR-101 over-
expression led to the downregulation of anti-apoptotic NF-κB
target genes in K562 cells, thereby promoting apoptosis. We
also showed that imatinib treatment enhanced the effect of
miR-101 overexpression on NF-κB-regulated anti-apoptotic
genes except for MCL-1 (Figs. 7c, 6b, c, 5e, f, 8, and 9).
Discussion
Based on previous studies, Jak2 is a critical signaling mole-
cule in Bcr–Abl+ cells [14, 42]. Xie et al. showed that Jak2
activation by Bcr–Abl induced c-Myc expression [12]. So, the
c-Myc mRNA level is inhibited either by the selective Bcr–
Abl tyrosine kinase inhibitor (imatinib) or by the Jak2 kinase
inhibitor (AG490). Hence, the Jak2/c-Myc pathway may play
an important role in CML progression that can be inhibited by
Jak2 inhibition.
Interestingly, Bcr–Abl activates the NF-κB pathway, which
leads to NF-κB-regulated gene expression [38]. It has been
reported that Jak2 is involved in NF-κB activation by Bcr–Abl
[39]. Given the Jak2 role in Bcr–Abl+ cells and its critical role
in tumorgenicity, it is not surprising that Jak2 inhibition con-
trols oncogenic mechanisms. Samanta et al. showed that Jak2
inhibition resulted in the apoptosis induction in leukemia cells
expressing imatinib-resistant forms of Bcr–Abl [14].
Therefore, Jak2 inhibitors have a potential for the treatment
of imatinib-resistant forms of CML.
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Fig. 8 Upregulated miR-101 exerts transcriptional suppression of
STAT5 target gene. Relative Bcl-xL mRNA expression (normalized to
GAPDH) after transduction with miR-101 by qPCR. miR-101 and NC-
transduced cells were treated with 250 nM imatinib for 72 h. The relative
expression of the indicated gene was measured using quantitative RT-
PCR and normalized to the expression of GAPDH. The figure shown is
a representative of at least three independent experiments (*P < 0.05
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Fig. 9 miR-101 overexpression decreases the NF-κB-regulated anti-
apoptotic genes. Survivin and XIAP downregulation (normalized to
GAPDH) in miR-101-transduced cells analyzed by real-time PCR.
miR-101 and NC-transduced cells were treated with 250 nM imatinib
for 72 h. The relative expression of survivin and XIAP was measured
using qPCR and normalized to the expression of GAPDH. The figure is a
representative of three independent qPCRs (*P < 0.05 relative to NC-
transduced cells)
Fig. 7 Upregulated miR-101 and imatinib treatment leads to miR-23a
overexpression. a miR-23a upregulation (normalized to RNU6) in
K562 and microRNA-transduced cells analyzed by real-time PCR.
miR-101 and NC-transduced cells were treated with 250 nM imatinib
for 72 h, and then the overexpression of miR-23a was measured using
quantitative RT-PCR and normalized to the expression of RNU6. b
STAT5, CCND1, and Bcl-2 are putative targets of miR-23a. Sequence
alignments of miR-23a with their corresponding potential target sites in
the 3′-UTR of STAT5, CCND1, and Bcl-2. The seed sequence of the
miRNA is bolded. c STAT5, CCND1, and Bcl-2 relative mRNA
expression (normalized to GAPDH) in transduced cells analyzed by
real-time PCR. Imatinib treatment of miR-101 and NC-transduced
K562 cells leads to STAT5, CCND1, and Bcl-2 downregulation in qRT-
PCR compared to untreated cells, which is associated with miR-101
expression. The figure is a representative of three independent qPCRs
(*P < 0.05 relative to NC-transduced cells)
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miRNAs are involved in multiple cellular processes includ-
ing proliferation, differentiation, and apoptosis [43].
Increasing amounts of data have shown that miRNAs can
act as oncogenes or tumor suppressors and participate in can-
cer development and progression [44].
According to the results of online prediction software, it
was found that miR-101 might pair the Jak2 3′-UTR. Given
the ectopic expression of miR-101 in the numerous cancer cell
lines and tissues [45], miR-101 acts as a cancer-related
miRNA. All target genes regulated by miR-101 have been
found to be involved in tumorigenesis; therefore, miR-101
can be considered a tumor suppressor in cancer therapy [45,
46]. Our present study is consistent with the results of a study
by Wang et al. [28] reporting that Jak2 is a direct target of
miR-101. In this study, we showed Jak2 upregulation and
miR-101 downregulation as a result of K562 leukemia cell
imatinib treatment. Our results also indicated that miR-101
overexpression in K562 cells resulted in Jak2 downregulation,
induced apoptosis, and enhanced imatinib-induced apoptosis.
However, whether miR-101 upregulation has any effect on the
Jak2 function and how the miR-101 mRNA level is regulated
during imatinib treatment remain to be investigated.
It has been reported that hTERT has a pivotal role in cellu-
lar immortalization. In most somatic cells, hTERT has a very
low expression and activity, while it is highly expressed and
has a high activity level in approximately 85 % of the tumors.
Uziel et al. demonstrated that imatinib repressed the telome-
rase activity in both Bcr–Abl-positive and Bcr–Abl-negative
cells [47] and telomerase inhibition could inversely augment
imatinib-induced apoptosis in K562 cells [48].
C-Myc, a potent regulator of telomerase, positively regu-
lates hTERT expression, which has been demonstrated in dif-
ferent cancers [49]. A positive correlation between c-Myc and
hTERT expression has been shown in leukemia cells by si-
lencing c-Myc mRNA leading to the inhibition of the telome-
rase activity [50]. It has been reported that Jak2 activation by
Bcr–Abl induces the expression of transcription factor c-Myc,
which is required for Bcr–Abl transformation [12, 31].
Given the role of Jak2 in enhancing c-Myc expression [12],
it seems that Jak2 downregulation may result in c-Myc and
hTERT mRNA repression. Our findings indicated that upreg-
ulation of miR-101 resulted in c-Myc and hTERT mRNA
repression due to Jak2 downregulation in k562 cells compared
to control cells. Furthermore, our data showed that miR-101
overexpression augmented the effect of imatinib on decreas-
ing c-Myc and hTERT mRNA levels. With regard to these
results, miR-101 overexpression can regulate the cell growth
by c-Myc and hTERT mRNA expression through Jak2
downregulation.
Across the various signaling pathways activated by Bcr–
Abl in CML cells, NF-κB may be the substantial pathway.
Interestingly, it has been reported that Jak2 is involved in
NF-κB activation by Bcr–Abl [39]. NF-κB promotes cell
growth through upregulation of key regulators of cell prolif-
eration such as c-Myc and CCND1 [51, 52]. In addition,
NF-κB suppresses apoptosis via regulating anti-apoptotic
genes such as Bcl-2, Bcl-xL, MCL-1, XIAP, and survivin
[38, 41] which are frequently overexpressed in human can-
cers. Given the fundamental role of NF-κB in the regulation of
apoptosis and cell survival [53], it is not surprising that the
inhibition of NF-κB leads to apoptosis. Our results indicated
that miR-101 could suppress anti-apoptotic and proliferative
genes regulated by NF-κB. In addition, miR-101 enhances the
effect of imatinib onNF-κB-regulated genes. Furthermore, we
showed that miR-101 overexpression and imatinib treatment
resulted in miR-23a upregulation. Interestingly, online predic-
tion tools show that miR-23a is a predicted miRNA for tran-
scription regulation of STAT5, CCND1, and Bcl-2 genes.
Therefore, the most straightforward interpretation of our re-
sults is that miR-23a may target key signals involved in the
survival of CML cells.
In conclusion, our findings showed that miR-101 sensitized
K562 leukemia cells to imatinib treatment through Jak2 re-
pression and miR-23a upregulation. Therefore, restoration of
miR-101 expression alone, or in combination with imatinib,
may be a potential therapeutic strategy for CML treatment.
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